PLA1A and cystic fibrosis: In the CF PDO model, de Poel et al. (14) demonstrated that the combination of ELX-02, the NMD inhibitor SMG1i, the correctors VX-445 and VX-661, and the potentiator VX-770 can significantly rescue CFTR function in organoids homozygous for W1282X-CFTR or homo-/heterozygous for G542X-CFTR.